Utility-Based Economic Assessment of Treatments

Treatment effectiveness was measured in LYs calculated from survival projections and QALYs (calculated from the time spent in each state combined with health-state utility [HSU] values).
Utility values for PF with stable disease and PF with response were derived from EuroQol 5-dimension 5-level (EQ-5D-5L) data collected in MONALEESA-2, which were converted to HSUs using a published value set. Since a U.S. value set for the EQ-5D-5L was not available, HSUs were calculated using the latest UK value set.^{25 (link)}Utility values for PD were obtained from the published literature because, in MONALEESA-2, EQ-5D-5L was collected up to only 1 month after progression, thereby limiting data capture to the immediate health consequences of PD. The study by Lloyd et al. (2006) was used; this study reported HSUs estimated via the standard gamble technique and has been used in previous economic studies.^{26 (link)}Disutility values associated with AEs (i.e., the effects of AEs on HSU) were also sourced from the literature. Table 1 shows the HSU values applied to the PF and PD health states and the disutility values associated with AEs presented by AE and mean AE duration.²⁷